Latest News

Discover how stem cell transplant still deepens myeloma remission, guided by MRD and paired with CAR‑T, bispecifics, and smarter maintenance.

Data from the KEYNOTE-B96 trial support the FDA approval of the pembrolizumab regimen in these gynecologic malignancies.

Nivolumab improved 9-year recurrence-free survival compared with ipilimumab for resected stage III or IV melanoma in the phase 3 CheckMate 238 trial.

According to Dominique Rash, MD, the incidence of inoperable endometrial cancer is rising in the US, and clinicians may encounter it more frequently.

In the future, the multiple myeloma field may gradually shift away from a continuous therapy model to more fixed-duration approaches.

Irpagratinib demonstrated superior survival among patients with hepatocellular carcinoma who were pretreated with ICIs and mTKIs.

A 5-year OS rate of 97.1% was observed among patients who received PSMA PET/CT restaging at first biochemical recurrence following prostatectomy.

Parul Barry, MD, discussed the evolving role of ADCs and targeted therapies in breast cancer, highlighting strategies for sequencing them with radiation.

Experts outline current initiatives from the American College of Radiation Oncology as well as potential next steps for advancing the field.

The multiple myeloma field may have even better treatment options available by the time some patients experience disease recurrence years down the line.

Confirmed antilymphoma responses occurred in 75% of patients with lymphoma, including 2 with a complete response and 2 with a partial response.

Supporting results for zenocutuzumab in patients with NRG1 fusion–positive CCA come from the phase 1/2 eNRGy trial.

Early data from the KYANITE-1 study support the RMAT designation for KB707 as a treatment for those with advanced or metastatic NSCLC.

The immune system is a “critical player” in the emergence and outcome of multiple myeloma, according to Manoj Bhasin, PhD, MS.

Because there are so many options available for treating DCIS, the chosen method is often based on the patient's preferences, said Jean L. Wright, MD, FASTRO.

Certain strategies are needed to improve clinical trial diversity, focusing on building patient trust, increasing workforce representation, and reducing logistical burdens.

Parul Barry, MD, discusses advances such as ultrahypofractionated radiation and the growing role of AI in streamlining workflows for breast cancer care.

Deb Schrag, MD, MPH, discusses her journey into GI oncology, the development of patient-reported outcome systems, and her vision for the upcoming ASCO presidency.

According to Jean L. Wright, MD, FASTRO, the flow of new information and research pertaining to ductal carcinoma in situ is constant.

The implementation of AI into radiomics may help predict the likelihood of response to therapies among patients undergoing breast cancer treatment.

From key clinical trial updates to reports on treatment disparities, the 2026 Tandem Meetings saw several critical developments in multiple myeloma.

CAR T-cell therapies displayed strong efficacy and manageable safety across lymphoma populations at the 2026 Tandem Meetings.

Theranostics, a technique that combines traditional medication with diagnostics, is “limitless”, according to Brandon Mancini, MD, MBA, FACRO.

Older age appeared to correlate with worse survival among those undergoing allogenic hematopoietic cell transplantation for acute lymphoblastic leukemia.

Kathie-Ann Joseph, MD, MPH, FACS, described the clinical criteria for nipple-sparing mastectomies and oncoplastic surgery, focusing on tumor-to-nipple distance and oncologic safety for breast cancer patients.

Based on the prevalence of GLP-1 agonists employed in standard medical practice, Li’s team will assess their impact on radiotherapy for prostate cancer.

Loaiza-Bonilla anticipates that AI-assisted EKG models could be cleared for use in risk stratification for receipt of surgery or drug use.

Theranostics is an escalating field within radiation oncology and clinicians should be utilizing it every day, according to Brandon Mancini, MD, MBA, FACRO.

J. Isabelle Choi, MD, outlined evidence-based strategies for radiation dose escalation in locoregionally advanced breast cancer.

No serious adverse effects were observed with TRX103 in patients with hematologic malignancies undergoing HLA-mismatched HCT.

Prior phase 1 data support the fast track designation for pelareorep as a treatment for those with KRAS-mutated microsatellite stable colorectal cancer.